Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Recaldent is a biotechnology company centered on the commercialization of Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP), a milk-derived protein technology that remineralizes tooth enamel. Developed at the University of Melbourne, the technology works by delivering bio-available calcium and phosphate to the tooth surface to repair early stages of decay and prevent cavities. The company operates primarily as a licensing entity, partnering with global dental and consumer health firms to integrate Recaldent into professional dental products and consumer goods like sugar-free chewing gum. Its primary commercial partners include GC Corporation, which manufactures professional topical crèmes, and various global confectionery brands.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Recaldent.